儿童甲状腺髓样癌:144例患者60年间的临床表现与长期结局
该回顾性研究分析了1961至2019年间在某三级转诊中心评估的144例年龄≤21岁甲状腺髓样癌(MTC)患者,其中散发性MTC(sMTC)20例(14%),遗传性MTC(hMTC)124例(86%)。与hMTC相比,sMTC患者年龄更大、肿瘤更大、初始分期更高,末次随访时结构性疾病和远处转移更多,但MTC特异性死亡风险无显著差异;在因临床表现而非家族史诊断的患者中,两组初始分期、诊断时远处转移、末次随访疾病状态及生存均无显著差异。12例sMTC行体细胞检测,11例(91%)发现可识别变异,包括10例RET基因变异和1例ALK融合。
要点
- sMTC占儿童起病MTC的14%(20/144),hMTC占86%(124/144)。
- sMTC较hMTC年龄更大、肿瘤更大、初始分期更高,末次随访结构性疾病和远处转移更多,但MTC特异性死亡无显著差异。
- 因临床表现诊断的sMTC与hMTC在初始分期、远处转移、疾病状态和生存上无显著差异。
核心结论
- sMTC主要是RET驱动性疾病,在本队列中占儿童起病MTC的14%。
- 儿童sMTC患者较hMTC年龄更大、就诊时临床疾病TNM分期更晚、末次随访持续性疾病更多,但这些差异在比较因临床表现就诊的患者时消失。
- 对于可能从全身治疗中获益的sMTC患者,应考虑体细胞分子检测。
研究设计与样本
- 回顾性研究,纳入1961年至2019年间诊断年龄≤21岁、在某三级转诊中心评估的144例MTC患者。
- 其中hMTC 124/144例(86%),sMTC 20/144例(14%)。
- 共77例因临床表现而非家族史诊断(sMTC 20/20例,hMTC 57/124例)。
- 12例sMTC肿瘤行体细胞检测。
主要发现
- sMTC患者较hMTC年龄更大(P < .0001),肿瘤更大(P < .0001),初始分期分组更高(P = .001)。
- sMTC患者末次随访时结构性疾病更多(P = .0045),远处转移更多(P = .00084),但死于MTC的可能性无显著差异(P = .42)。
- 在77例因临床表现诊断的患者中,初始分期(P = .27)、诊断时远处转移(P = 1.0)、末次随访疾病状态(P = .13)、总生存(P = .57)和疾病特异性生存(P = .87)均无显著差异。
- 12例sMTC行体细胞检测,11例(91%)有可识别变异:10例RET基因变异和1例ALK融合。
临床怎么用
- 作者认为,对于可能从全身治疗中获益的sMTC患者,应考虑体细胞分子检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Sporadic medullary thyroid carcinoma (sMTC) rarely occurs in childhood and no studies have specifically focused on this entity. OBJECTIVE: To describe the clinical presentations and long-term outcomes of a large cohort of children and young adults with sMTC compared with hereditary MTC (hMTC). METHODS: Retrospective study of 144 patients diagnosed with MTC between 1961 and 2019 at an age ≤ 21 years and evaluated at a tertiary referral center. RESULTS: In contrast to hMTC (n = 124/144, 86%), patients with sMTC (n = 20/144, 14%) are older (P < .0001), have larger tumors (P < .0001), a higher initial stage grouping (P = .001) and have more structural disease (P = .0045) and distant metastases (DM) (P = .00084) at last follow-up, but are not more likely to die from MTC (P = .42). Among 77 patients diagnosed clinically, not by family history (20/20 sMTC and 57/124 hMTC), there was no difference in the initial stage (P = .27), presence of DM at diagnosis (P = 1.0), disease status at last follow-up (P = .13), overall survival (P = .57), or disease-specific survival (P = .87). Of the 12 sMTC tumors that underwent somatic testing, 11 (91%) had an identifiable alteration: 10 RET gene alterations and 1 ALK fusion. CONCLUSION: sMTC is primarily a RET-driven disease that represents 14% of childhood-onset MTC in this cohort. Pediatric sMTC patients are older, present with clinical disease at a more advanced TNM classification, and have more persistent disease at last follow-up compared with hMTC, but these differences disappear when comparing those presenting clinically. Somatic molecular testing should be considered in sMTC patients who would benefit from systemic therapy.
引用
- Hensley SG, Hu MI, Bassett RL, et al. Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-Term Outcomes in 144 Patients Over 6 Decades. J Clin Endocrinol Metab. 2024. PMID: 38441533. doi:10.1210/clinem/dgae133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。